Literature DB >> 8816405

Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage.

M Hakoda1, N Kamatani, S Hayashimoto-Kurumada, G J Silverman, H Yamanaka, C Terai, S Kashiwazaki.   

Abstract

Human IgM that express the variable region genes of the VH3 family bind staphylococcal protein A (SPA). We previously reported that the SPA-binding IgM can be divided into two groups based on the differential binding avidities for solid-phase SPA. To study the molecular basis for these differences, we cloned B cells from human blood by EBV transformation. The nucleotide sequences of the expressed Ig heavy chain genes were determined on 20 B cell clones that produce SPA-binding IgM. The germ-line VH3 gene usage in IgM with high avidities for SPA were distinct from the germ-line VH3 genes used in IgM with low avidities for SPA. There was no correlation in the usage of D or JH genes or in the usage of light chains in IgM according to the SPA binding avidity. These results suggest that the differential binding avidities for SPA are at least partly due to specific germ-line VH3 gene usage. An investigation of direct binding of SPA to the synthetic peptides corresponding to the portions of the variable regions of SPA-binding and non-SPA-binding IgM showed that the peptides corresponding to the VH3 family specific framework region 3 sequences had significant SPA binding capacities, while the peptides corresponding to the other subdomains and those corresponding to framework region 3 of the reported VH3 sequences from non-SPA-binding IgM showed little or no binding. It is of interest that the Ig-framework region 3 subdomain corresponds to the fourth hypervariable region, which in the TCR-beta chain has been implicated as a critical site for T cell superantigen binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816405

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity.

Authors:  M Graille; E A Stura; A L Corper; B J Sutton; M J Taussig; J B Charbonnier; G J Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

Review 3.  B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies.

Authors:  Carl S Goodyear; Gregg J Silverman
Journal:  Springer Semin Immunopathol       Date:  2005-03

4.  B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions.

Authors:  J Voswinkel; A Mueller; J A Kraemer; P Lamprecht; K Herlyn; K Holl-Ulrich; A C Feller; S Pitann; A Gause; W L Gross
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

5.  Development of a robust method for establishing B cell lines using Epstein-Barr Virus.

Authors:  Inaho Danjoh; Hiyori Sone; Ryoko Shirota; Takashi Hiroyama; Yukio Nakamura
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

6.  A checkpoint for autoreactivity in human IgM+ memory B cell development.

Authors:  Makoto Tsuiji; Sergey Yurasov; Klara Velinzon; Saskia Thomas; Michel C Nussenzweig; Hedda Wardemann
Journal:  J Exp Med       Date:  2006-01-30       Impact factor: 14.307

7.  Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins.

Authors:  M Léonetti; J Galon; R Thai; C Sautès-Fridman; G Moine; A Ménez
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.